Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Neuropsychologia. 2016 Sep 6;91:407–414. doi: 10.1016/j.neuropsychologia.2016.09.006

Fig. 5.

Fig. 5

Displayed is the cross-subject relationship between AB magnitude in the baseline condition (OFF medication) and the on L-DOPA (left panel) and on DA agonist only (right panel) conditions. L-DOPA tended to decrease the AB in patients with a large baseline AB and to increase the AB in patients with a small baseline AB. DA agonists did not modulate the AB as a function of baseline AB magnitude. Note that dual therapy patients are included in both plots, as they performed the AB task both on only L-DOPA and only on a DA agonist.